<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581840</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 0904</org_study_id>
    <nct_id>NCT01581840</nct_id>
  </id_info>
  <brief_title>Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus</brief_title>
  <official_title>Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment is based on radiochemotherapy for locally advanced tumours. The objective of
      treatment is to provide a cure without resorting to abdominoperineal amputation, while
      preserving sphincter function.

      The prognosis is mainly related to tumour size and lymph node invasion. The large majority of
      patients do not show any spread remote from the tumour at the time of diagnosis (2).

      Recurrences are mainly of a local/regional nature and require abdominoperineal amputation.
      This type of intervention is not always possible or complete, which then gives rise to the
      particularly distressing risk of local progression, with survival at 3 years of approximately
      30% (3).

      It is therefore very important to achieve a complete and permanent tumour response from
      initial treatment with radiochemotherapy.

      Furthermore, the use of an anti-EGFR antibody in combination with exclusive radiotherapy in
      ENT cancer was able to increase recurrence-free survival and overall survival in these
      patients. These data are in favour of the use of a combination of chemotherapy and anti-EGFR
      antibodies in epidermoid cancer of the anus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I = determination the maximum tolerated dose 5FU and panitumumab in combination with radiotherapy and mitomycin, and thereby to deduce the maximum tolerated dose in patient with localised epidermoid carcinoma of the anus</measure>
    <time_frame>9 weeks after the beginning of treatment</time_frame>
    <description>Phase I = determine the dose limiting toxicity of 5FU and panitumumab in combination with radiotherapy and mitomycin, and thereby to deduce the maximum tolerated dose in patient with localised epidermoid carcinoma of the anus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II = Complete response of the tumor rectal examination and morphological exams</measure>
    <time_frame>8 weeks evaluations after the end of the treatment by radiochemotherapy</time_frame>
    <description>phase II = Response criteria: complete desappearance of the tumor upon rectal examination and morphological exams (MRI, endoscopic ultrasonography) and non appearance of secondary lesions, response validated by an independant committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II = Partial response rate, stable disease and progression</measure>
    <time_frame>6 weeks and 17 weeks after the beginning of treatment</time_frame>
    <description>Intermediate objective response rate (complete and partial) at 6 weeks (before the additional radiotherapy). The 80% reduction rate in the largest tumour diameter will also be recorded.
Partial response rate, stable disease and progression 8 weeks after the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Colostomy-free survival</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Recurrence-free survival at 3 years</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Overall survival</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Quality of life (EORTC QLQ-C30 + Wexner questionnaire)</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Epidermoid Carcinoma</condition>
  <condition>Anus</condition>
  <arm_group>
    <arm_group_label>5Fu-mitomycine-panitumumab + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radiochemotherapy</intervention_name>
    <description>Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²</description>
    <arm_group_label>5Fu-mitomycine-panitumumab + radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>3 or 6 mg/kg (according to dose level)</description>
    <arm_group_label>5Fu-mitomycine-panitumumab + radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven epidermoid carcinoma of the anus

          -  Locally advanced tumour without metastases

          -  Stage T2&gt;3 cm or T3 or T4, irrespective of N

          -  Stage N1-N3 irrespective of T stage (T1 to T4)

          -  General condition WHO 0-1

          -  Life expectancy &gt; 3 months

          -  Signed informed consent form

          -  Age &gt; 18 years

          -  Effective contraception in female and/or male patients having reached sexual maturity
             during treatment and up to 6 months after the end of treatment

          -  CD4 &gt; 400 / mm3

          -  Measureable tumor on at least one of the following exams : MRI, endoscopic
             ultrasonography, clinical exam

        Exclusion Criteria:

          -  Presence of metastases

          -  Previous anti-EGFR therapy

          -  Stage T1N0 or T2 &lt; 3 cm N0

          -  History of pelvic radiotherapy

          -  At least one of the following laboratory test results: Neutrophils &lt; 1500 /mm3,
             platelets &lt; 100 000 /mm3, Hb &lt; 9 g/dl, leukocytes &lt; 3000/mm3, blood bilirubin &gt; 1.5
             times the upper limit of the normal range, transaminase (ASAT and ALAT) &gt; 2.5 times
             the upper limit of the normal range, creatinine clearance &lt; 50 mL/min (Cockcroft's
             formula Appendix x), Mg2+ &lt; the lower limit of the normal range, Ca2+ &lt; the lower
             limit of the normal range

          -  Significant coronary artery disease or myocardial infarction in the past year

          -  Follow-up not possible due to psychological or geographic reasons

          -  History of interstitial pneumonitis or pulmonary fibrosis

          -  History of malignant disease in the past five years apart from basocellular skin
             carcinoma or in situ cervical carcinoma having received adequate treatment

          -  Pregnant or breast-feeding women, women of child-bearing potential not having taken a
             pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique VENDRELY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Haut-Lévêque - Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Moreau</last_name>
    <phone>+33 3 80 39 34 04</phone>
    <email>marie.moreau@u-bourgogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas APARICIO</last_name>
      <email>thomas.aparicio@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas APARICIO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Radiothérapie Haute Energie</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine LEVY</last_name>
      <email>chrispiedbois@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Christine LEVY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas APARICIO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte HENRIQUES</last_name>
      <email>b.henriques@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Bénédicte HENRIQUES</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique BECHADE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianne FONCK</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves BECOUARN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pessac - Hôpital Haut Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique VENDRELY</last_name>
      <email>veronique.vendrely@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique VENDRELY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric TERREBONNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie PESQUE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie CHAPUIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazid BELKACEMI</last_name>
      <email>yazid.belkacemi@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yazid BELKACEMI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elias ASSAF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie et de radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arianne DARUT-JOUVE</last_name>
      <email>ariane.jouve@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Arianne DARUT-JOUVE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Christine BONE-LEPINOY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geneviève BOILLOT-JOLIMOY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier MIRABEL</last_name>
      <email>x-mirabel@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier MIRABEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaovi AMELA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farid EL HAJBI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle DE LA FOURCHARDIERE</last_name>
      <phone>04 26 55 67 31</phone>
    </contact>
    <investigator>
      <last_name>Christelle DE LA FOURCHARDIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise DESSEIGNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard LLEDO</last_name>
      <email>glledo@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Gérard LLEDO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laëticia DAHAN</last_name>
      <email>laetitia.dahan@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laëticia DAHAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François SEITZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle NORGUET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murielle DULUC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire LEMANSKI</last_name>
      <email>Claire.Lemanski@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Claire LEMANSKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen LLACER MOSCARDO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier PEIFFERT</last_name>
      <email>d.peiffert@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Didier PEIFFERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry CONROY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Christine KAMINSKY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Sophie BAUMANN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Agathe SERRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent QUERO</last_name>
      <email>laurent.quero@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent QUERO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DE LA ROCHEFORDIERE</last_name>
      <email>anne.de-la-rochefordiere@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DE LA ROCHEFORDIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe LE TOURNEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Paule SABLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona POP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique DIERAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cario - HPCA - Hôpital privé des Côtes D'Armor</name>
      <address>
        <city>Plérin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Luc ETIENNE</last_name>
      <email>pl.etienne@cario-sante.fr ; pl.etienne@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Luc ETIENNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique BESSON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Claire HARDY-BESSARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid LIEVRE</last_name>
      <email>astrid.lievre@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Astrid LIEVRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe PERRIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien EDELINE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie TALARMIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry LESIMPLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid LIEVRE</last_name>
      <email>astrid.lievre@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Astrid LIEVRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion RICHARD-MOLARD</last_name>
      <email>marion.richard-molard@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Marion RICHARD-MOLARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara DIEUMEGARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>May MABRO</last_name>
      <email>m.mabro@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>May MABRO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LECOMTE</last_name>
      <email>thierry.lecomte@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry LECOMTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie CHAPET</last_name>
      <email>s.chapet@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie CHAPET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry LECOMTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anus</keyword>
  <keyword>carcinoma</keyword>
  <keyword>panitumumab</keyword>
  <keyword>mitomycine</keyword>
  <keyword>5Fu</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

